Refractory Follicular Lymphoma (DBCOND0041114)

Identifiers

Synonyms

Follicular Lymphoma-Refractory / Refractory B-Cell Lymphoma / B-cell Lymphoma Refractory / Refractory Lymphoma, B-Cell / Lymphoma, B-Cell Refractory / B-cell non-Hodgkin's lymphoma refractory

Associated Data

Indicated Drugs and Targets

Drug	Description	Targets
Axicabtagene ciloleucel	A CAR T-cell therapy used to treat adults with large B-cell lymphomas and follicular lymphoma.	B-lymphocyte antigen CD19target
Epcoritamab	A bispecific CD20-directed CD3 T-cell engager used to treat relapsed or refractory diffuse large B-cell lymphoma (DLBCL) in adults.	B-lymphocyte antigen CD20target T-cell surface glycoprotein CD3 epsilon chaintarget
Hyaluronidase (ovine)	A purified form of sheep hyaluronidase enzyme used as an adjunct in subcutaneous rehydration therapy and to increase absorption of other drugs and radiopaque imaging agents.	Transforming growth factor beta-1 proproteintarget Albumincarrier Hyaluronantarget
Lisocabtagene maraleucel	A CAR T-cell therapy for treatment resistant or more severe B-cell lymphomas.	B-lymphocyte antigen CD19target
Obinutuzumab	An antineoplastic CD20 antibody used to treat untreated chronic lymphocytic leukemia in combination with chlorambucil.	B-lymphocyte antigen CD20target
Tazemetostat	A methyltransferase inhibitor indicated to treat patients 16 years and older with metastatic or locally advanced epithelioid sarcoma not eligible for complete resection.	Histone-lysine N-methyltransferase EZH2target ATP-dependent translocase ABCB1transporter Multidrug and toxin extrusion protein 1transporter Multidrug and toxin extrusion protein 2transporter Cytochrome P450 3A Subfamilyenzyme Histone-lysine N-methyltransferase EZH1target Broad substrate specificity ATP-binding cassette transporter ABCG2transporter Cytochrome P450 3A4enzyme
Tisagenlecleucel	A CAR T cell therapy for relapsed or refractory large B-cell lymphoma and diffuse large B-cell lymphoma.	B-lymphocyte antigen CD19target
Umbralisib	A kinase inhibitor used to treat rare forms of refractory lymphoma.	ATP-dependent translocase ABCB1transporter Cytochrome P450 2C9enzyme Cytochrome P450 1A2enzyme Cytochrome P450 3A4enzyme Casein kinase I isoform epsilontarget Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit delta isoformtarget Tyrosine-protein kinase ABL1target
Zanubrutinib	A kinase inhibitor used to treat mantle cell lymphoma, a type of B-cell non-Hodgkin lymphoma, in adults who previously received therapy.	Cytochrome P450 3A4enzyme ATP-dependent translocase ABCB1transporter Cytochrome P450 2B6enzyme Tyrosine-protein kinase BTKtarget Epidermal growth factor receptortarget Receptor tyrosine-protein kinase erbB-2target Receptor tyrosine-protein kinase erbB-4target Tyrosine-protein kinase ITK/TSKtarget Cytoplasmic tyrosine-protein kinase BMXtarget Tyrosine-protein kinase JAK2target Tyrosine-protein kinase Tectarget Tyrosine-protein kinase Blktarget Tyrosine-protein kinase JAK3target Protein-tyrosine kinase 6target Tyrosine-protein kinase Fgrtarget Tyrosine-protein kinase FRKtarget Tyrosine-protein kinase Lcktarget Tyrosine-protein kinase TXKtarget Cytochrome P450 3A Subfamilyenzyme

Clinical Trials

Identifier	Title	Drug(s)	Purpose	Phase	Status
NCT06209619	CC-99282 + Rituximab Early Post CART for Non-Hodgkin's Lymphoma	Golcadomide Rituximab	treatment	1	recruiting
NCT03824951	Study of Anti-CD19 iCAR NK Cells in Relapsed and Refractory B Cell Lymphoma	Natural Killer Cell	treatment	0	unknown_status
NCT05003141	PSB202 in Patients With Previously Treated-, Relapsed-, Indolent B-Cell Malignancies	No drug interventions	treatment	1	unknown_status
NCT03692767	Study of Anti-CD22 CAR NK Cells in Relapsed and Refractory B Cell Lymphoma	Natural Killer Cell	treatment	0	unknown_status
NCT06378190	Treatment of Relapsed or Refractory B-cell Lymphoma With Chimeric Antigen Receptor (CAR) T-cell Therapy Produced by a New Technology	No drug interventions	treatment	1 / 2	recruiting
NCT03824964	Study of Anti-CD19/CD22 CAR NK Cells in Relapsed and Refractory B Cell Lymphoma	Natural Killer Cell	treatment	0	unknown_status
NCT04300998	Study of CAR-T Therapy in Older Patients	No drug interventions	Not Available	Not Available	recruiting
NCT06158386	Chidamide Combined With Linperlisibon for the Treatment of Refractory/Relapsed Follicular Lymphoma	Linperlisib Tucidinostat	treatment	2	recruiting
NCT03690310	Study of Anti-CD19 CAR NK Cells in Relapsed and Refractory B Cell Lymphoma	Natural Killer Cell	treatment	0	unknown_status
NCT04531046	Axi-Cel as a 2nd Line Therapy in Patients With Relapsed/Refractory Aggressive B Lymphoma Ineligible to Autologous Stem Cell Transplantation	Axicabtagene ciloleucel	treatment	2	active_not_recruiting
NCT03853616	MB-CART19.1 R/r CD19+ B-cell Malignancies (BCM)	Tisagenlecleucel	treatment	1 / 2	recruiting
NCT06445803	CD19/CD22 CAR-T Cells in Adults With R/R ALL or NHL	No drug interventions	treatment	1	recruiting
NCT05909098	Safety and Efficacy of Autologous NK Cell Adjuvant Therapy for Relapsed/Refractory Non-Hodgkin's B-cell Lymphoma	No drug interventions	treatment	1 / 2	not_yet_recruiting
NCT05705570	A Phase I Clinical Trial Using Genetically Engineered Autologous T Cells to Express Chimeric Antigen Receptor (CAR) for Treatment of Patients With Refractory or Relapsed CD19-positive B Lymphoid Malignancies	Cyclophosphamide Fludarabine	treatment	1	not_yet_recruiting
NCT01786018	Thiotepa, Busulfan and Fludarabin for pt With Refractory/Early Relapsed Aggressive B-cell Non Hodgkin Lymphomas	Busulfan Cyclosporine Fludarabine Methotrexate Thiotepa	treatment	2	unknown_status
NCT03664635	MB-CART20.1 Lymphoma	No drug interventions	treatment	1 / 2	active_not_recruiting
NCT05130489	CAR T Cell Therapy Related Cardiovascular Outcomes	No drug interventions	Not Available	Not Available	completed
NCT05645744	Long-term Follow-up Study in Patients Previously Treated With a Mustang Bio CAR-T Cell Investigational Product.	MB-102 CD123 CAR	Not Available	Not Available	terminated
NCT05360238	Study to Assess Safety, Tolerability and Efficacy of MB-106 in Patients With Relapsed or Refractory B-Cell NHL or CLL	No drug interventions	treatment	1 / 2	terminated
NCT04303247	CD19 and CD22 Dual-targeted CAR-T Cells for Relapsed or Refractory B-NHL	No drug interventions	treatment	0	unknown_status
NCT06220097	Mitoxantrone Hydrochloride Liposome Injection-containing Bridging Regimen and CD19-targeting CAR-T Therapies	Fludarabine Mitoxantrone	treatment	2	recruiting
NCT04747093	Induced-T Cell Like NK Cells for B Cell Malignancies	No drug interventions	treatment	1 / 2	unknown_status
NCT06552559	Selinexor With ICE Chemotherapy in Secondary Central Nervous System Involving B-cell Non-Hodgkin Lymphoma	Carboplatin Dexamethasone Etoposide Ifosfamide Selinexor	treatment	1 / 2	recruiting
NCT05318963	Targeting CD19/CD20/CD22 Triple-targeted Cell in Patients With Relapsed/Refractory B-cell Lymphoma	No drug interventions	treatment	1	recruiting
NCT04214886	CD19 Chimeric Antigen Receptor (CAR) T Cells for Adults With Recurrent or Refractory B Cell Malignancies	Cyclophosphamide Fludarabine	treatment	1	active_not_recruiting
NCT01535989	Study of Inotuzumab Ozogamicin + Temsirolimus in Patients With Relapsed or Refractory CD22+ B-cell NHLymphoma	Inotuzumab ozogamicin Temsirolimus	treatment	1	completed
NCT04304040	A Study of MIL62 Combined With Orelabrutinib for the Treatment of R/R CD20+B Cell Lymphoma	Orelabrutinib	treatment	1 / 2	active_not_recruiting
NCT05828589	A Study of BGB-21447, a Bcl-2 Inhibitor, in Mature B-Cell Malignancies	No drug interventions	treatment	1	recruiting
NCT06343376	Genetically Engineered Cells (EGFRt/19-28z/IL-12 CAR T Cells) for the Treatment of Relapsed or Refractory CD19+ Hematologic Malignancies	Cyclophosphamide Fludarabine	treatment	1	recruiting
NCT01955499	Lenalidomide and Ibrutinib in Treating Patients With Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma	Ibrutinib Lenalidomide	treatment	1	active_not_recruiting
NCT03269669	Obinutuzumab With or Without Umbralisib, Lenalidomide, or Combination Chemotherapy in Treating Patients With Relapsed or Refractory Grade I-IIIa Follicular Lymphoma	Bendamustine Cortisone Cyclophosphamide Doxorubicin Lenalidomide Obinutuzumab Prednisone Sulfate ion Umbralisib Vincristine	treatment	2	active_not_recruiting
NCT04224493	A Study to Assess the Efficacy, Safety, Pharmacodynamics, and Pharmacokinetics of Tazemetostat in Combination With Lenalidomide Plus Rituximab Versus Placebo in Combination With Lenalidomide Plus Rituximab in Adult Patients at Least 18 Years of Age With Relapsed/Refractory Follicular Lymphoma.	Lenalidomide Rituximab Tazemetostat	treatment	3	recruiting
NCT04578600	CC-486, Lenalidomide, and Obinutuzumab for the Treatment of Recurrent or Refractory CD20 Positive B-cell Lymphoma	Azacitidine Lenalidomide Obinutuzumab	treatment	1	active_not_recruiting
NCT05025800	ALX148, Rituximab and Lenalidomide for the Treatment of Indolent and Aggressive B-cell Non-Hodgkin Lymphoma	Evorpacept Lenalidomide Rituximab	treatment	1 / 2	recruiting
NCT02927964	TLR9 Agonist SD-101, Ibrutinib, and Radiation Therapy in Treating Patients With Relapsed or Refractory Grade 1-3A Follicular Lymphoma	Ibrutinib Toll-like receptor 9	treatment	1 / 2	completed
NCT04195633	Donor Stem Cell Transplant With Treosulfan, Fludarabine, and Total-Body Irradiation for the Treatment of Hematological Malignancies	Cyclophosphamide Cyclosporine Filgrastim Fludarabine Mycophenolate mofetil Mycophenolic acid Treosulfan	treatment	2	recruiting
NCT02568553	Lenalidomide and Blinatumomab for the Treatment of Relapsed Non-Hodgkin Lymphoma	Blinatumomab Lenalidomide Muromonab	treatment	1	active_not_recruiting
NCT03401853	Pembrolizumab With Rituximab or Obinutuzumab in Treating Patients With Relapsed or Refractory Follicular Lymphoma or Diffuse Large B Cell Lymphoma	Obinutuzumab Pembrolizumab Rituximab	treatment	2	active_not_recruiting
NCT04635683	Lenalidomide, Umbralisib, and Ublituximab for the Treatment of Relapsed or Refractory Indolent Non-Hodgkin Lymphoma or Mantle Cell Lymphoma	Lenalidomide Ublituximab Umbralisib	treatment	1	withdrawn
NCT04699461	Study to Evaluate the Efficacy and Safety of Loncastuximab Tesirine Versus Idelalisib in Participants With Relapsed or Refractory Follicular Lymphoma	Idelalisib Loncastuximab tesirine	treatment	2	terminated
NCT04205409	Nivolumab for Relapsed, Refractory, or Detectable Disease Post Chimeric Antigen Receptor T-cell Treatment in Patients With Hematologic Malignancies	Nivolumab	treatment	2	active_not_recruiting
NCT04836832	Acalabrutinib and Duvelisib for the Treatment of Relapsed/Refractory Indolent Non-Hodgkin Lymphoma	Acalabrutinib Duvelisib Tyrosine	treatment	1	withdrawn
NCT05152459	Tazemetostat in Combination With Umbralisib and Ublituximab for the Treatment Relapsed or Refractory Follicular Lymphoma	Tazemetostat Ublituximab Umbralisib	treatment	1 / 2	withdrawn
NCT00723099	Donor Umbilical Cord Blood Transplant in Treating Patients With Hematologic Cancer	Cyclophosphamide Cyclosporine Fludarabine Mycophenolate mofetil	treatment	2	completed
NCT05604417	Zandelisib + Tazemetostat in R/R Follicular Lymphoma	Tazemetostat Zandelisib	treatment	1 / 2	withdrawn
NCT05453396	Loncastuximab Tesirine for the Treatment of Relapsed or Refractory B-Cell Malignancies	Loncastuximab tesirine	treatment	2	recruiting
NCT02992522	Obinutuzumab, Venetoclax, and Lenalidomide in Treating Patients With Relapsed or Refractory B-cell Non-Hodgkin Lymphoma	Lenalidomide Obinutuzumab Venetoclax	treatment	1	active_not_recruiting
NCT02956382	Ibrutinib and Venetoclax in Relapsed and Refractory Follicular Lymphoma	Ibrutinib Venetoclax	treatment	1 / 2	active_not_recruiting
NCT03150329	Pembrolizumab and Vorinostat in Patients With Relapsed or Refractory DLBCL, FCL or HL.	Pembrolizumab Vorinostat	treatment	1	active_not_recruiting
NCT04007029	Modified Immune Cells (CD19/CD20 CAR-T Cells) in Treating Patients With Recurrent or Refractory B-Cell Lymphoma or Chronic Lymphocytic Leukemia	Cyclophosphamide Fludarabine Tocilizumab	treatment	1	recruiting
NCT01381692	Bortezomib, Rituximab, and Dexamethasone With or Without Temsirolimus in Treating Patients With Untreated or Relapsed Waldenstrom Macroglobulinemia or Relapsed or Refractory Mantle Cell or Follicular Lymphoma	Bortezomib Bortezomib D-mannitol Dexamethasone Menthol Rituximab Sirolimus Temsirolimus	treatment	1 / 2	completed
NCT06068881	A Study to Assess Efficacy and Safety of Oral Tazemetostat in Adult Participants With Relapsed/Refractory Follicular Lymphoma That Does Not Have an "EZH2 Gain-of-function" Genetic Mutation	Tazemetostat	treatment	2	not_yet_recruiting
NCT06191887	B-Cell Activating Factor Receptor (BAFFR)-Based Chimeric Antigen Receptor T-Cells With Fludarabine and Cyclophosphamide Lymphodepletion for the Treatment of Relapsed or Refractory B-cell Hematologic Malignancies	Bendamustine Cyclophosphamide Fludarabine	treatment	1	recruiting
NCT04587687	Brentuximab Vedotin and Bendamustine for the Treatment of Relapsed or Refractory Follicular Lymphoma	Bendamustine Brentuximab vedotin	treatment	2	recruiting
NCT02869633	Ibrutinib in Treating Patients With Refractory or Relapsed Lymphoma After Donor Stem Cell Transplant	Ibrutinib	treatment	2	completed
NCT03598998	Pembrolizumab and Pralatrexate in Treating Patients With Relapsed or Refractory Peripheral T-Cell Lymphomas	Pembrolizumab Pralatrexate	treatment	1 / 2	active_not_recruiting
NCT03147885	Selinexor Plus Combination Chemotherapy in Treating Patients With Advanced B Cell Non-Hodgkin Lymphoma	Escitalopram Selinexor	treatment	1 / 2	recruiting
NCT03583424	Venetoclax, Carmustine, Etoposide, Cytarabine, and Melphalan Before Stem Cell Transplant in Treating Participants With Relapsed or Refractory Non-Hodgkin Lymphoma	Beta-D-Glucose Carmustine Cytarabine Etoposide Mechlorethamine Venetoclax	treatment	1 / 2	unknown_status
NCT04447716	An Early Phase Study of Venetoclax, Lenalidomide, and Rituximab/Hyaluronidase in Slow-Growing Lymphomas That Have Come Back After Treatment or Have Not Responded to Treatment	Hyaluronidase (human recombinant) Lenalidomide Rituximab Venetoclax	treatment	1	recruiting
NCT03015896	Nivolumab and Lenalidomide in Treating Patients With Relapsed or Refractory Non-Hodgkin or Hodgkin Lymphoma	Lenalidomide Nivolumab	treatment	1 / 2	active_not_recruiting
NCT01849263	Ibrutinib in Treating Patients With Relapsed or Refractory Follicular Lymphoma	Ibrutinib	treatment	2	active_not_recruiting
NCT05848765	Relapsed Follicular Lymphoma Randomised Trial Against Standard ChemoTherapy	Bendamustine Cyclophosphamide Doxorubicin Epcoritamab Lenalidomide Obinutuzumab Prednisone Rituximab Vincristine	treatment	2	recruiting
NCT02950220	Pembrolizumab and Ibrutinib in Treating Patients With Relapsed or Refractory Non-Hodgkin Lymphoma	Ibrutinib Pembrolizumab	treatment	1	completed
NCT03579927	CAR.CD19-CD28-zeta-2A-iCasp9-IL15-Transduced Cord Blood NK Cells, High-Dose Chemotherapy, and Stem Cell Transplant in Treating Participants With B-cell Lymphoma	Beta-D-Glucose Carmustine Cytarabine Etoposide Filgrastim Mechlorethamine Natural Killer Cell Rituximab	treatment	1 / 2	withdrawn
NCT02332980	Pembrolizumab Alone or With Idelalisib or Ibrutinib in Treating Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia or Other Low-Grade B-Cell Non-Hodgkin Lymphomas	Ibrutinib Idelalisib Pembrolizumab	treatment	2	completed
NCT03277729	A Phase I/II Study to Evaluate the Safety of Cellular Immunotherapy Using Autologous T Cells Engineered to Express a CD20-Specific Chimeric Antigen Receptor for Patients With Relapsed or Refractory B Cell Non-Hodgkin Lymphomas	Cyclophosphamide Fludarabine	treatment	1 / 2	active_not_recruiting
NCT03019640	Umbilical Cord Blood NK Cells, Rituximab, High-Dose Chemotherapy, and Stem Cell Transplant in Treating Patients With Recurrent or Refractory B-Cell Non-Hodgkin's Lymphoma	Allogeneic natural killer cells Beta-D-Glucose Carmustine Cytarabine Etoposide Filgrastim Lenalidomide Mechlorethamine Natural Killer Cell Rituximab	treatment	2	completed
NCT03479268	Pevonedistat and Ibrutinib in Treating Participants With Relapsed or Refractory CLL or Non-Hodgkin Lymphoma	Ibrutinib Pevonedistat	treatment	1	active_not_recruiting
NCT01995669	Lenalidomide and Obinutuzumab in Treating Patients With Relapsed Indolent Non-Hodgkin Lymphoma	Lenalidomide Obinutuzumab	treatment	1 / 2	completed
NCT01897012	Alisertib and Romidepsin in Treating Patients With Relapsed or Refractory B-Cell or T-Cell Lymphomas	Alisertib Romidepsin	treatment	1	completed
NCT00498914	Study of YM155 in Refractory Diffuse Large B-cell Lymphoma (DLBCL) Subjects	Sepantronium	treatment	2	terminated